The global cardiac resynchronization therapy market size was valued at USD 5.09 billion in 2025 and is projected to grow from USD 5.31 billion in 2026 to USD 7.48 billion by 2034, registering a CAGR of 4.37% during the forecast period from 2026 to 2034. North America dominated the cardiac resynchronization therapy market with a market share of 41.5% in 2025.
The cardiac resynchronization therapy market is growing steadily as cardiovascular diseases, particularly heart failure, continue to rise globally, with over 64 million people affected worldwide. Aging populations and lifestyle risks are key contributors. Increasing awareness of early diagnosis is improving adoption of advanced CRT devices. Leading companies such as Medtronic, Abbott Laboratories, and Boston Scientific are driving innovation with MRI-compatible devices and remote monitoring systems, enhancing treatment outcomes.
Download a Free Sample To learn more about this report,
Adoption of Quadripolar Left Ventricular Leads in Cardiac Resynchronization Therapy
The need for greater flexibility in selecting left ventricular pacing sites is encouraging the adoption of quadripolar leads in cardiac resynchronization therapy. This transition provides multiple pacing configurations from a single lead, helping clinicians adjust pacing sites and avoid some lead-positioning challenges during CRT. For example, Abbott’s Quartet quadripolar LV lead has four electrodes and supports up to 14 pacing configurations, providing additional options for LV pacing.
Integration of Remote Patient Monitoring With Cardiac Resynchronization Therapy
The need for continuous follow-up after CRT implantation is encouraging the integration of remote monitoring systems with cardiac resynchronization therapy devices. This transition allows device information and selected cardiac data to reach clinicians remotely, supporting earlier identification of device issues or abnormal heart rhythms and reducing the need for some routine in-person checks. For example, Medtronic’s remote monitoring system can automatically transmit information from compatible CRT devices to the clinic through a home communicator or smartphone-based system.
Heart Failure Management and Cardiology Service Access Drive Market
The need for better management of chronic heart failure creates demand for therapies that can improve cardiac function and support long-term patient care. Healthcare providers consider cardiac resynchronization therapy for eligible patients whose ventricular contraction is poorly coordinated and contributes to heart failure symptoms. For example, CRT devices can coordinate the contractions of the left and right ventricles in selected heart failure patients with electrical conduction abnormalities. This treatment requirement supports demand for CRT systems, implantation procedures, and related cardiac-care services.
Improved access to specialized cardiology and electrophysiology services creates greater capacity for evaluating patients and performing complex cardiac device procedures. Hospitals with trained electrophysiologists and dedicated cardiac-device programs can identify suitable patients and provide CRT implantation and follow-up care. For example, a specialized electrophysiology center can assess ECG and echocardiography results before determining whether a patient is suitable for CRT. This healthcare infrastructure supports broader utilization of CRT devices and expands access to related implantation services.
CRT Response Variability and Lead Placement Challenges Restrain Market Expansion
Limited response to CRT occurs in a substantial proportion of treated patients, with reviews commonly reporting non-response rates of about 30% to 50%. Factors such as myocardial scar, suboptimal lead position, and differences in electrical activation can reduce the clinical benefit of therapy and make patient selection more complex. This variability in treatment response can reduce physician confidence and slow the adoption of cardiac resynchronization therapy.
Complex coronary venous anatomy can make left ventricular lead placement difficult because of tortuous, narrow, short, or otherwise unsuitable veins. A review of CRT implantation anatomy notes that unfavorable branch characteristics can create technical challenges during lead delivery and positioning. These procedural challenges can increase implantation complexity and limit the adoption of CRT in patients with difficult anatomy.
MRI-Compatible CRT Systems and Strategic Cardiac Care Partnerships Offers Growth Opportunities
Cardiac device manufacturers and electrophysiology providers can develop CRT systems that allow eligible patients to undergo MRI examinations under specified conditions. Medtronic’s Cobalt XT HF Quad CRT-D is MR Conditional and supports 1.5T and 3T MRI under specified conditions, creating revenue through premium device portfolios and hospital procurement.CRT manufacturers, hospitals, electrophysiology centers, and cardiology networks can collaborate on device programs, implantation support, and technical training. Medtronic’s CRT portfolio includes multiple systems with therapy and diagnostic features, providing scope for long-term device supply and clinical support agreements with cardiac-care providers.
Device Validation and Hospital Infrastructure Hinders Growth
CRT manufacturers must conduct extensive testing to demonstrate device safety, reliability, and clinical performance before commercialization. The FDA states that PMA applications for applicable Class III devices require valid scientific evidence, including nonclinical and clinical investigations, to establish safety and effectiveness. These requirements can increase R&D expenditure and extend product-development timelines, making market entry more difficult for smaller device manufacturers.
CRT implantation requires specialized electrophysiology facilities, cardiac imaging capabilities, device-programming systems, and appropriate post-procedure monitoring. The FDA's approval of the WiSE CRT System illustrates the specialized clinical infrastructure involved, with the system intended for patients requiring CRT who meet specific clinical and implantation conditions. Hospitals with limited infrastructure may therefore need additional investment and specialized capabilities, restricting the geographic expansion of CRT technologies.
The transvenous CRT-D segment accounted for a share of 52.8% in 2025, owing to its widespread use in patients requiring cardiac resynchronization and defibrillation, along with established clinical adoption and proven device performance. the increasing prevalence of heart failure and growing adoption of advanced cardiac rhythm management technologies further strengthen the segment’s dominant position in the cardiac resynchronization therapy market.
The sub-cutaneous CRT-D segment is expected to grow at a CAGR of 6.08% during the forecast period, driven by increasing demand for less invasive cardiac device solutions, growing adoption of advanced defibrillation technologies, and rising awareness of alternative implantation approaches. the single-chamber CRT-P segment supports cardiac resynchronization in selected patients requiring pacing therapy, while the dual/biventricular CRT-P segment contributes through synchronized ventricular pacing for patients with cardiac conduction abnormalities and heart failure.
Request Customizationto receive a tailored report.
The hospitals segment accounted for a share of 55.7% in 2025 due to the widespread use of cardiac resynchronization therapy in heart failure management, advanced cardiac procedures, and rhythm disorders. the availability of specialized cardiologists, advanced cardiac care infrastructure, and comprehensive treatment facilities further strengthens the segment’s dominant position in the cardiac resynchronization therapy market.
The ambulatory surgical centers segment is expected to grow at a CAGR of 6.12% during the forecast period, fueled by the increasing shift toward outpatient cardiac procedures, growing adoption of minimally invasive interventions, and rising demand for cost-effective healthcare services. the cardiac centers segment supports specialized cardiac rhythm management and heart failure treatment, while the other end users segment includes additional healthcare settings providing cardiac resynchronization therapy and related services.
Speak to an Analystto discuss market opportunities.
The North America cardiac resynchronization therapy market accounted for the largest regional share of 41.5% in 2025, driven by the high prevalence of cardiovascular diseases, advanced cardiac care infrastructure, and increasing adoption of implantable cardiac devices. The U.S. cardiac resynchronization therapy market is supported by a substantial heart failure population, with the American Heart Association reporting that approximately 6.7 million U.S. adults are living with heart failure, with prevalence projected to exceed 8 million by 2030. The growing heart failure burden and need for advanced therapies support demand for cardiac resynchronization therapy and related cardiac devices.
The Canada cardiac resynchronization therapy market is supported by the continued burden of heart failure, with Canada’s Chronic Disease Surveillance System recording 134,460 new heart failure cases among people aged 40 years and older in 2023–2024, corresponding to an age-standardized incidence rate of 646 per 100,000. This substantial disease burden supports continued demand for advanced cardiac therapies, including cardiac resynchronization therapy.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cardiac resynchronization therapy market is expected to grow at a CAGR of 6.71%, showcasing the fastest-growing regional market, driven by rising cardiovascular disease burden, improving healthcare infrastructure, and increasing access to advanced cardiac treatment technologies. In Japan, the National Cerebral and Cardiovascular Center continues to maintain procurement and medical-equipment purchasing programs in 2026, including cardiovascular-related medical equipment and supplies, with procurement information updated in September 2026, reflecting ongoing investment in specialized cardiovascular care infrastructure.
In China, the National Health Commission issued a July 2026 policy requiring centralized procurement of medical equipment purchased by public healthcare institutions using budgeted funds. The policy requires national- and provincial-level centralized procurement and aims to complete at least one procurement round by the end of 2026, supporting more structured acquisition of specialized cardiovascular medical equipment. In South Korea, the Health Insurance Review & Assessment Service maintains specific reimbursement criteria for cardiac resynchronization therapy, including CRT-pacemaker procedures for selected heart-failure patients, supporting continued clinical use of CRT within the national health insurance system. In India, the government eProcurement system records a procurement tender for Cardiac Resynchronisation Therapy-Pacing/Defibrillator (CRT-P/CRT-D) with a tender value of ₹80 lakh, demonstrating institutional demand for cardiac resynchronization devices in the Indian healthcare system.
The Europe cardiac resynchronization therapy market accounted for a regional share of 28.4% in 2025, supported by well-established healthcare systems, increasing adoption of advanced cardiac therapies, and growing demand for effective heart failure management. In the U.K. cardiac resynchronization therapy market, NHS England includes implantable cardioverter-defibrillators with cardiac resynchronisation therapy (CRT) capabilities within its national specialised-services device programme. NHS commissioning also maintains dedicated adult cardiology services for implantable cardioverter-defibrillator and cardiac resynchronisation therapy, supporting continued institutional provision of CRT devices.
In the Germany cardiac resynchronization therapy market, the 2026 ESC heart-failure guidelines, presented in Munich in August 2026, provide updated recommendations covering advances in heart-failure therapies, including device-based treatment. In addition, results presented at ESC Congress 2026 in Munich showed continued clinical research into CRT, with the DANISH-CRT trial evaluating lead-placement strategies for patients undergoing cardiac resynchronization therapy, supporting ongoing development of CRT technologies. Meanwhile, the France cardiac resynchronization therapy market is supported by the Haute Autorité de Santé (HAS), which continues to evaluate cardiac resynchronization devices. Its assessment of the ALLURE RF triple-chamber pacemaker recognizes CRT for selected patients with symptomatic chronic heart failure, including patients with LVEF ≤35% and specified QRS-duration criteria. In 2026, HAS also continued updating heart-failure treatment recommendations, supporting the clinical framework for cardiac-device therapies.
The Middle East and Africa cardiac resynchronization therapy market is expected to grow at a CAGR of 5.09%, supported by improving cardiac care facilities, rising awareness of heart failure treatment, and increasing investments in advanced healthcare infrastructure. The UAE cardiac resynchronization therapy market is expected to benefit from Abu Dhabi’s expansion of advanced cardiovascular care, with the Department of Health – Abu Dhabi reporting in June 2026 that its Centres of Excellence had delivered specialized care for more than 3,000 complex cases since their launch in 2023, including advanced adult and pediatric cardiovascular care, supported by advanced healthcare infrastructure, medical innovations, and research.
The Africa cardiac resynchronization therapy market is expected to benefit from efforts to expand access to specialized cardiovascular care, with WHO reporting in July 2026 that more than 170,000 people had accessed facilities providing PEN-Plus services across 20 African countries over three years, including screening, diagnosis, treatment, long-term care, and referral for severe cardiovascular conditions such as rheumatic and congenital heart diseases.
The cardiac resynchronization therapy market is moderately consolidated, with medical device manufacturers, cardiovascular technology companies, cardiac rhythm management specialists, implantable device providers, and healthcare technology companies competing across hospitals, cardiac care centers, and specialized cardiovascular treatment settings. Established players compete primarily on device reliability, clinical efficacy, technological innovation, battery performance, lead technology, programming capabilities, product safety, regulatory compliance, research and development, physician support, and global distribution networks, with leading players such as Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, and MicroPort Scientific Corporation estimated to account for approximately 75% of the global market based on their product portfolios, technological capabilities, geographic presence, and competitive positioning.
Emerging and regional players within the cardiac resynchronization therapy market ecosystem compete through cost-effective devices, compact designs, improved implantation features, customized solutions, specialized cardiac technologies, flexible manufacturing, localized distribution, and rapid product development to address specific cardiovascular care requirements and strengthen their market presence. These players also focus on developing advanced device features, improving implantation efficiency, and expanding specialized cardiac solutions to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Germany Surgical Equipment Market Size, Share and Forecast to 2034
Europe Surgical Equipment Market Size, Top Share and Forecast to 2034
Biofeedback Instrument Market Size, Share, Growth, Analysis, 2034
Cardiac Assist Devices Market Size, Share, Growth, 2034
Radiosurgery Market Size, Share, Growth, Analysis, Report, 2034
Interventional Cardiology Devices Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com